29 April 2016 Financial Summary +-------------------+-----+----+------+ | | $m | % change | +-------------------+-----+----+------+ | | |CER1|Actual| +-------------------+-----+----+------+ |Total Revenue2 |6,115| 5 | 1 | +-------------------+-----+----+------+ | | | | | +-------------------+-----+----+------+ |Core3 Op. Profit |1,593|(8) | (12) | +-------------------+-----+----+------+ |Core EPS |$0.95|(7) | (12) | +-------------------+-----+----+------+ | | | | | +-------------------+-----+----+------+ |Reported Op. Profit|1,038| 17 | 11 | +-------------------+-----+----+------+ |Reported EPS |$0.51| 26 | 17 | +-------------------+-----+----+------+  · Total Revenue grew by 5%, driven by a significant increase in Externalisation Revenue · Core R&D costs increased by 15%, reflecting recent acquisitions; Core R&D costs declined versus Q4 2015 · Core SG&A costs fell by 6% and represented 35% of Total Revenue (Q1 2015: 39%) · Core EPS declined by 7%, reflecting a significant reduction in Other Operating Income · Reported Operating Profit grew by 17% to $1,038m. Reported EPS grew by 26% to $0.51 · FY 2016 CER guidance unchanged Commercial Highlights The Growth Platforms grew by 6%, representing 56% of Total Revenue: 1. Respiratory: +2%. Growth of Pulmicort and newly-acquired medicines offset by a decline in sales of Symbicort 2. Brilinta/Brilique: +46%. Continued encouraging progress; post-MI approval in the EU 3. Diabetes: +23%. Strong sales growth included an increase of +65% in Emerging Markets. Global Farxiga/Forxiga growth of 128% 4. Emerging Markets: +6%. Good China sales growth of +11%; slowdowns in other regions 5. Japan: -7%, reflecting destocking ahead of mandated biennial price reductions from April 2016 6. New Oncology: Contributed $99m. Launch of Tagrisso in key markets progressing well Click on, or paste the following link into your web browser, to view the associated PDF document. http://www.rns-pdf.londonstockexchange.com/rns/7481W_1-2016-4-28.pdf

Ads